Atopic dermatitis (AD) is a type of inflammation of the skin. It results in itchy, swollen, red, and cracked skin. Mesenchymal Stem Cells (MSCs) could suppress allergic responses in AD. Indeed, the immunomodulatory ability of MSCs can be usefully applied for the treatment of autoimmune and inflammation – related diseases such as asthma, rhinitis and dermatitis. We aims to evaluate safety and efficacy in DNFB – induced atopic dermatitis mouse model after a subcutaneous infusion of xenogeneic human Adipose Tissue – derived MSCs (hAT-MSCs). Therefore, hAT-MSCs have possibility as a new drug for AD.